Novel Agents That Downregulate EGFR, HER2, and HER3 in Parallel

Oncotarget - United States
doi 10.18632/oncotarget.3398
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Author Correction: HER Kinase Inhibition in Patients With HER2- And HER3-mutant Cancers

Nature
Multidisciplinary
2019English

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

EGFR and HER2 Signaling in Breast Cancer Brain Metastasis

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2016English

Pd28-09 Abnormal Her2 and Her3 Signalling in Prostate Cancer: Potentials for Clinical Application.

Journal of Urology
Urology
2016English

EGFR and HER2 Expression in Advanced Biliary Tract Cancer

Zeitschrift fur Gastroenterologie
MedicineGastroenterology
2008English

HER2-HER3 Dimer Quantification by FLIM-FRET Predicts Breast Cancer Metastatic Relapse Independently of HER2 IHC Status

Oncotarget
Oncology
2016English

Positive Prognostic Value of HER2-HER3 Co-Expression and P-mTOR in Gastric Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies

Oxidative Medicine and Cellular Longevity
BiochemistryMedicineCell BiologyAging
2016English

Inhibition of EGFR, HER2, and HER3 Signalling in Patients With Colorectal Cancer Wild-Type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): A Phase 2–3 Randomised Trial

Lancet Gastroenterology and Hepatology, The
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy